A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to treat patients with muscle-invasive bladder cancer. Wednesday, May 29, 2019 Dr. Wassim Kassouf is a urologic oncologist working at the McGill University Health Center, the CCTG BL12 study chair and is currently a member of the clinical trials committee in genito-urinary diseases. Dr. Kassouf maintains that the BL13 trial will help evaluate whether combination therapy improves the disease control locally but also in terms of distant metastases and survival. This study has the potential to be a groundbreaking study because in Canada, half of the patients do not get any definitive therapy for this disease, so it will further that large unmet need as well as provide an opportunity to improve cure rate. CCTG BL13: A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer. NCT Registration ID (from clinicaltrials.gov): NCT037 Objectives: The overall objective of this phase II randomized trial is to determine if Durvalumab when used in combination following standard trimodality therapy improves disease-free-survival in patients with muscle-invasive bladder cancer who are electing for bladder-sparing treatment. For more information please visit the CCTG BL13 trial page.
